Harvard Bioscience (HBIO) Gains from Investment Securities (2023)
Harvard Bioscience's (HBIO) quarterly Gains from Investment Securities came in at $259000.0 in Q4 2023, up 121.44% on a QoQ basis from -$1.2 million in Q3 2023.
Harvard Bioscience (HBIO) Gains from Investment Securities (2023) Analysis & Trends
Harvard Bioscience (HBIO) has 1 years of Gains from Investment Securities data on file, last reported at $259000.0 in Q4 2023.
- On a quarterly basis, Gains from Investment Securities changed N/A year-over-year to $259000.0 in Q4 2023; TTM through Dec 2023 was $632000.0, a N/A change from a year earlier, with the FY2024 full-year figure at $1.6 million, up 152.06% from the prior year.
- Gains from Investment Securities for Q4 2023 stood at $259000.0, up from -$1.2 million in the prior quarter.
- Over the last five years, Gains from Investment Securities for HBIO reached as high as $1.6 million in Q2 2023 and fell as low as -$1.2 million in Q3 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Intuitive Surgical | 126.32 Bn | 121.10 Bn | 1.96 Bn |
| 2 | Becton Dickinson | 44.69 Bn | 43.88 Bn | 2.15 Bn |
| 3 | Alcon | 32.80 Bn | 31.14 Bn | 1.53 Bn |
| 4 | Medline | 32.72 Bn | 30.49 Bn | 1.84 Bn |
| 5 | Resmed | 29.54 Bn | 27.88 Bn | 890.98 Mn |
| 6 | West Pharmaceutical Services | 23.56 Bn | 23.13 Bn | 329.20 Mn |
| 7 | Solventum | 14.00 Bn | 13.44 Bn | 1.10 Bn |
| 8 | Cooper Companies | 13.75 Bn | 13.61 Bn | 735.40 Mn |
| 9 | Align Technology | 12.03 Bn | 10.97 Bn | 736.59 Mn |
| 10 | Harvard Bioscience | 26.75 Mn | 19.65 Mn | 12.24 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 259,000.00 |
| Dec 31, 2023 | 259,000.00 |
| Sep 30, 2023 | -1.21 Mn |
| Sep 30, 2023 | -1.21 Mn |
| Jun 30, 2023 | 1.58 Mn |
| Jun 30, 2023 | 1.58 Mn |